Natchaya Vanwong
1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
Sadeep Medhasi
1. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
2. Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand
Manat Pongchaidecha
Department of Pharmaceutics (Clinical Pharmacy), Faculty of Pharmacy, Silpakorn University, Sanamchandra Palace Campus, Nakhon Pathom, Thailand
Nattawat Ngamsamut
Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, Thailand
Apichaya Puangpetch
1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
Montri Chamnanphon
1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
Bhunnada Chamkrachchangpada
Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, Thailand
Teerarat Tan-kam
Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, Thailand
Yaowaluck Hongkaew
1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
Penkhae Limsila
Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, Thailand
Chonlaphat Sukasem
1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
Abstract
Background: Risperidone produces marked adverse effects including weight gain which often causes patients to discontinue the treatment. However, if patients continue to receive further treatment, increasing weight gain was found to increase a risk of clinically significant obesity and several health problems. Objective: To investigate the factors associated with risperidone-related weight gain in Thai autistic spectrum disorder patients. Methods: We conducted a retrospective and observational study among Thai autistic patients treated with risperidone. The data collected included risperidone dose, sex, age, body weight and BMI baseline, concomitant drug therapy, duration of drug used, and phenotype/genotype of CYP2D6 responsible for body weight gain during risperidone therapy. Results: Univariate analysis showed that factors affecting the body weight gain among risperidone-treated Thai autistic patients were duration of risperidone treatment (months) (P<0.0001), cumulative dose (P<0.0001), age (P=0.001) and BMI baseline (P<0.01). Multivariable analysis showed that factors affecting the body weight gain were duration of treatment (months) (P=0.011), baseline age (P=0.002) and age (P<0.0001). Conclusions: This study makes a preliminary contribution to provide opportunities for personalized medicine in the predictive assessment of weight gain and to minimize the risk for metabolic syndrome in risperidone-treated Thai patients.
